Literature DB >> 16522371

Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.

Xiaocai Yan1, Rimas J Orentas, Bryon D Johnson.   

Abstract

Macrophage migration inhibitory factor (MIF) is a multi-functional cytokine that is considered a pro-inflammatory cytokine. However, our studies show that MIF, when produced in super-physiological levels by a murine neuroblastoma cell line (Neuro-2a) exceeding those normally seen during an immune response, inhibits cytokine-, CD3-, and allo-induced T-cell activation. MIF is also able to inhibit T cells that have already received an activation signal. The T-cell inhibitory effects of culture supernatants from neuroblastoma cells were reversed when the cells were transfected with dicer-generated si-RNA to MIF. When T cells were activated in vitro by co-culture with interleukin (IL)-2 and IL-15 and analyzed for cytokine production in the presence or absence of MIF-containing culture supernatant, inhibition of T-cell proliferation and induced cell death were observed even as the treated T cells produced high levels of interferon-gamma (IFN-gamma). The inhibitory effects of MIF were partially reversed when lymphocytes from IFN-gamma knockout mice were tested. We propose that the high levels of MIF produced by neuroblastoma cause activation induced T-cell death through an IFN-gamma pathway and may eliminate activated T cells from the tumor microenvironment and thus contribute to escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522371      PMCID: PMC2018658          DOI: 10.1016/j.cyto.2006.01.006

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  55 in total

Review 1.  Fas ligand-induced apoptosis.

Authors:  S Nagata
Journal:  Annu Rev Genet       Date:  1999       Impact factor: 16.830

2.  STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma.

Authors:  C K Lee; E Smith; R Gimeno; R Gertner; D E Levy
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

3.  Relative contribution of different receptor subtypes in the response of neuroblastoma cells to tumor necrosis factor-alpha.

Authors:  F Condorelli; M A Sortino; A M Stella; P L Canonico
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

4.  Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells.

Authors:  J Knezevic-Cuca; K B Stansberry; G Johnston; J Zhang; E T Keller; A I Vinik; G L Pittenger
Journal:  J Neuroimmunol       Date:  2000-01-03       Impact factor: 3.478

5.  Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells.

Authors:  A C Repp; E S Mayhew; S Apte; J Y Niederkorn
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis.

Authors:  T Shimizu; R Abe; H Nakamura; A Ohkawara; M Suzuki; J Nishihira
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

7.  Angiogenesis and neuroblastomas: interleukin-8 and interleukin-8 receptor expression in human neuroblastoma.

Authors:  F A Ferrer; A G Pantschenko; L J Miller; K Anderson; M Grunnet; P H McKenna; D Kreutzer
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

Review 8.  Molecular biology of neuroblastoma.

Authors:  J M Maris; K K Matthay
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

9.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.

Authors:  A Kamimura; M Kamachi; J Nishihira; S Ogura; H Isobe; H Dosaka-Akita; A Ogata; M Shindoh; T Ohbuchi; Y Kawakami
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

10.  Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis.

Authors:  Nicole D Powell; Tracey L Papenfuss; Melanie A McClain; Ingrid E Gienapp; Todd M Shawler; Abhay R Satoskar; Caroline C Whitacre
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

View more
  20 in total

1.  The IL-25-dependent tuft cell circuit driven by intestinal helminths requires macrophage migration inhibitory factor (MIF).

Authors:  Fumi Varyani; Stephan Löser; Kara J Filbey; Yvonne Harcus; Claire Drurey; Marta Campillo Poveda; Orhan Rasid; Madeleine P J White; Danielle J Smyth; François Gerbe; Philippe Jay; Rick M Maizels
Journal:  Mucosal Immunol       Date:  2022-03-14       Impact factor: 7.313

2.  Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.

Authors:  Kristen M Barr; Weiqing Jing; William H D Hallett; Jill A Gershan; Bryon D Johnson
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

3.  Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Authors:  Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-25       Impact factor: 4.553

4.  Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.

Authors:  Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

Review 5.  The role of macrophage migration inhibitory factor on glucose metabolism and diabetes.

Authors:  C Toso; J A Emamaullee; S Merani; A M J Shapiro
Journal:  Diabetologia       Date:  2008-07-09       Impact factor: 10.122

6.  Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo.

Authors:  Qiang Zhou; Xiaocai Yan; Jill Gershan; Rimas J Orentas; Bryon D Johnson
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

7.  MIF homologues from a filarial nematode parasite synergize with IL-4 to induce alternative activation of host macrophages.

Authors:  Lidia Prieto-Lafuente; William F Gregory; Judith E Allen; Rick M Maizels
Journal:  J Leukoc Biol       Date:  2009-01-29       Impact factor: 4.962

Review 8.  The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal-maternal interface.

Authors:  Paola Viganò; Marcella Cintorino; Frederick Schatz; Charles J Lockwood; Felice Arcuri
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 11.759

9.  ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models.

Authors:  Kyriaki Ioannou; Kai Fan Cheng; Gregg V Crichlow; Anastasios I Birmpilis; Elias J Lolis; Ourania E Tsitsilonis; Yousef Al-Abed
Journal:  Int J Oncol       Date:  2014-07-22       Impact factor: 5.650

10.  Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses.

Authors:  Kristen N Balogh; Dennis J Templeton; Janet V Cross
Journal:  PLoS One       Date:  2018-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.